ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 225

Polymyositis in HIV+ Patients Is Associated to Uncontrolled Viral Load

Yves Allenbach1, Odile Dubourg2, Thierry Maisonobe2, Anthony Behin3, Charles Duyckaerts2, Guillaume Breton4, Olivier Fain5, Marie-Caroline Meyhoas6, Catherine Leport7, Marc-Antoine Valentin8, Daniel Vittecoq9, Jean-François Bergmann10, Thomas Anslik11, Marie-Paule Chauveheid12, Zahir Amoura13, Thomas de Broucker14, Pierre Bourgeois15, Bruno Eymard3, Serge Herson16 and Olivier Benveniste17, 1Internal Medicine Dpt 1, Pitié-Salpêtrière Hospital, APHP, Paris, France, 2Neuropathology, Pitie-Salpetriere Hospital, Paris, France, 3Institute of Myology, Pitie-Salpetriere Hospital, Paris, France, 4Internal Medecine, Pitie-Salpetriere Hospital, Paris, France, 5Internal Medicine, Jean Verdier Hospital, Bondy, France, 6Department of Infectious Diseases, Saint Antoine Hospital, Paris, France, 7Epidemic and biological risk coordination unit, AP-HP, Paris, France, 8Department of Infectious Diseases, Pitié-Salpetriere Hospital, Paris, France, 9Department of Infectious Diseases, K Bicetre Hospital, Kremlin-Bicetre, France, 10Internal Medicine, Lariboisiere Hospital, Paris, France, 11Internal Medicine, Ambroise Pare Hospital, Boulogne Billancourt, France, 12Internal Medicine,, University Paris-7, APHP, Bichat Hospital, Paris, France, 13Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, 14Department of Neurology, Delafontaine Hospital, Saint Denis, France, 15Rheumatology, APHP,Pitie-Salpetriere Hospital, Paris 6, Paris, France, 16Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University, Paris, France, 17Internal Medecine Dpt 1, Pitié-Salpêtrière Hospital, APHP, Paris, France

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: polymyositis/dermatomyositis (PM/DM) and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Muscle Biology, Myositis and Myopathies: Clinical and Therapuetic Aspects of Idiopathic Inflammatory Myopathies

Session Type: Abstract Submissions (ACR)

Background/Purpose: Different myopathies can be observed in HIV-infected patients, such as idiopathic inflammatory myopathies (inclusion-body myositis or polymyositis) or toxic mitochondrial myopathies secondary to antiretroviral therapy. The frequency and the evolution of those different myopathies is not precisely known, thus we aimed to describe all HIV patients from our center who presented a myopathy.  

Methods: We conducted a systematic review of computerised database of the department of pathology to select HIV infected patients who underwent a muscle biopsy during the 2005-2011 periods. For each biopsies, morphological (hematein eosin staining), mitochondrial (Gomori trichrome, succinic dehydrogenase and cytochrome oxidase staining) and immunological (HLA1, lymphocytes subclasses staining) analyses were performed.

Results: During the studied period, 2880 muscle biopsies were performed. Fifty biopsies (1.7%) were realised in 45 HIV+ patients (mean age: 50.1 years [39-61,2]).

Among the 50 biopsies, 43 were abnormal. The most frequently observed myopathy was polymyositis (60%). Among pathologicaly diagnosed polymyositis during this period of time (n=161), 23 (14%) were diagnosed in HIV+ patients. After polymyositis, mitochondrial abnormalities were the most frequently observed lesions (54%, myositis and mitochondrial abnormalities beeing observed concomitantly in some patients). Five cases (13%) of inclusion body myositis were also pathologically diagnosed.

Compared to a cohort of 50 anti-synthetase syndrome patients (with anti-Jo1 Abs), HIV polymyositis patients had a less severe weakness (MRC manual testing ≥ 4/5 83% in HIV+  vs. 54% for Jo1+ patients p<0.05) and lower CK levels (1677 vs. 4975 IU/L, p<0.05). Muscle weakness disappeared within six months after steroid treatments and/or highly active antiretroviral therapy introduction or modification. HIV viral load was detectable (125.186±21.295 copies/ml) for 80% of polymyositis patients whereas it was undetectable for all patients with isolated mitochondrial abnormalities (p<0.01). For the 7 patients with isolated mitochondrial abnormalities (suggesting mitochondrial toxicity), nucleoside-analogue reverse-transcriptase inhibitors were stopped for another highly active antiretroviral therapy combination, in the frame of an interventional study (the Myotox trial). Two years latter, no significant change concerning either muscular symptoms, CK level or pathological features of mitochondrial abnormalities were observed after this intervention.

Conclusion: This retrospective study showed that polymyositis is the most frequent HIV associated myopathy, and suggested that a HIV test must be proposed to every patient presenting a polymyositis. Polymyositis in HIV patients seemed not severe, and is associated with uncontrolled HIV replication. HIV patients with isolated mitochondriopathy did not improve after nucleoside-analogue reverse-transcriptase inhibitors withdrawal.


Disclosure:

Y. Allenbach,
None;

O. Dubourg,
None;

T. Maisonobe,
None;

A. Behin,
None;

C. Duyckaerts,
None;

G. Breton,
None;

O. Fain,
None;

M. C. Meyhoas,
None;

C. Leport,
None;

M. A. Valentin,
None;

D. Vittecoq,
None;

J. F. Bergmann,
None;

T. Anslik,
None;

M. P. Chauveheid,
None;

Z. Amoura,
None;

T. de Broucker,
None;

P. Bourgeois,
None;

B. Eymard,
None;

S. Herson,
None;

O. Benveniste,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/polymyositis-in-hiv-patients-is-associated-to-uncontrolled-viral-load/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology